NCT06387628View on ClinicalTrials.gov

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2027

Conditions
TNBC - Triple-Negative Breast Cancer
Interventions
DRUG

LM-108

LM-108, 10mg/kg, d1, q6w

DRUG

Toripalimab

Toripalimab, 240 mg, d1, q3w

DRUG

Eribulin

Eribulin 1.4 mg/m2, d1, 8 , q3w

DRUG

Nab paclitaxel

Nab paclitaxel 125 mg/m2, d1, 8 , q3w

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER